Protalix Biotherapeutics (PLX) Osake Kurssi
Protalix Biotherapeutics Kurssi
Viimeisten 19 vuoden aikana Protalix Biotherapeuticsn liikevaihto kasvoi 36,1 % vuodessa ja ylsi 52,74 M USD:een. Osakekohtainen tulos on laskenut 43,1 % vuodessa viimeisten 9 vuoden aikana. Protalix Biotherapeuticsn nettomarginaali −12,5 % on noussut verrattuna −71,9 %:iin muutama vuosi sitten. Protalix Biotherapeuticsn 12 kuukauden konsensustavoitehinta on 6,00 USD, noin yli kurssia 103,4 %. 5 analyytikosta 4 suosittaa ostoa — kokonaiskonsensus on Osta.
Protalix Biotherapeutics osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Protalix Biotherapeutics liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Protalix Biotherapeutics -osakkeesta
The business model of Protalix Biotherapeutics Inc revolves around developing and commercializing innovative recombinant protein therapeutics. As a biopharmaceutical company, Protalix utilizes its proprietary plant cell-based protein expression system, ProCellEx®, to produce therapeutic proteins. This advanced technology enables Protalix to produce biologic drugs with improved safety, efficacy, and cost-effectiveness compared to traditional methods. The company focuses on developing treatments for rare and orphan diseases, such as Fabry disease and Gaucher disease. By leveraging its unique plant-based platform, Protalix aims to address unmet medical needs and provide patients with access to life-changing therapies.
Protalix Biotherapeutics Inc is primarily active in the pharmaceutical industry.
The main competitors of Protalix Biotherapeutics Inc in the market are Genzyme Corporation, Shire plc, and Pfizer Inc.
Protalix Biotherapeutics Inc is a leading biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins. Founded in 1993, Protalix has a rich history of innovation and breakthroughs in the field of biotechnology. The company has pioneered the use of plant cell-based expression system, ProCellEx®, to produce high-quality therapeutic proteins. This proprietary technology enables the efficient and cost-effective production of complex proteins with enhanced stability and bioactivity. Protalix has achieved significant milestones, including the first FDA-approved plant cell-based therapy, and continues to advance its diverse pipeline of potential treatments for various diseases. With a commitment to delivering groundbreaking therapies, Protalix Biotherapeutics Inc remains at the forefront of the biopharmaceutical industry.
Protalix Biotherapeutics Inc has achieved several significant milestones. Firstly, the company received FDA approval for its drug, Elelyso, in 2012. Elelyso is an enzyme replacement therapy used for the treatment of Gaucher disease. Additionally, Protalix successfully developed and manufactured Taliglucerase alfa, a plant cell-expressed recombinant protein, becoming the first company to gain regulatory approval for a plant cell-based biopharmaceutical. In 2020, the company announced positive results from Phase III clinical trials for pegunigalsidase alfa, a potential therapy for Fabry disease. These achievements exemplify Protalix Biotherapeutics Inc's dedication to advancing biopharmaceuticals and improving patient outcomes. (Note: As an AI language model, I don't have real-time information and the mentioned achievements may not be up-to-date. It's always recommended to refer to the company's official sources for the most recent and accurate information.)
Protalix Biotherapeutics Inc is primarily present in various countries and regions around the world. The company is actively engaged and has a strong presence in the United States and Israel, where its headquarters are located. Additionally, Protalix Biotherapeutics Inc has expanded its operations and partnerships to other countries, including Europe, Latin America, and Asia. Through strategic collaborations and distribution agreements, the company aims to provide its innovative biopharmaceutical solutions to patients globally. Protalix Biotherapeutics Inc's commitment to international expansion allows it to reach a wider audience and explore new markets for its cutting-edge therapies.
Protalix Biotherapeutics Inc represents values of innovation, dedication, and patient-focused healthcare. The company believes in pushing boundaries to develop novel biologic therapies for challenging medical conditions. By harnessing its proprietary ProCellEx® plant cell-based protein expression system, Protalix aims to deliver high-quality, cost-effective treatments to patients worldwide. The company's corporate philosophy revolves around a commitment to scientific excellence, integrity, and improving the lives of individuals affected by rare diseases. Protalix Biotherapeutics Inc stands as a leading biopharmaceutical company dedicated to transforming the future of healthcare through breakthrough therapies and compassionate patient care.
Analyytikot asettavat tällä hetkellä Protalix Biotherapeutics-osakkeelle keskimääräisen tavoitehinnan 6,00 USD (mediaani: 6,00 USD), mikä merkitsee +103,4 % viimeisimpään hintaan verrattuna. Konsensus perustuu 5 analyytikkoarvioon.
Protalix Biotherapeutics Analyytikkojen kursstavoitteet 2026
5 analyytikkoa arvioi tällä hetkellä Protalix Biotherapeutics-osaketta: 4 suosittaa ostoa, 1 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Protalix Biotherapeutics-yhtiöltä 82,14 M USD liikevaihtoa ja 0,25 USD osakekohtaista tulosta.
Protalix Biotherapeutics Analyytikkojen kursstavoitteet 2026
Nykyisellä valuuttakurssilla Protalix Biotherapeutics-osake noteerataan hintaan 2,65 EUR (2,95 USD).
Protalix Biotherapeutics-osake (PLX) on listattuna 4 pörssissä, muun muassa: Frankfurt (PBDA.F), München (PBDA.MU), Düsseldorf (PBDA.DU).
Protalix Biotherapeutics Inc is a leading company in the field of biotechnology and biopharmaceuticals. The company specializes in the development and production of therapeutics based on enzymes and is an important player in the industry. The company's business model is based on the development, production, and marketing of biological products for the treatment of rare diseases, with a focus on the production of therapeutic enzymes for the treatment of lysosomal storage diseases. Protalix Biotherapeutics Inc has proven to be a leader in research and development in recent years, with an extensive pipeline of potential biological products. Its core product is Elelyso, a recombinant human glucocerebrosidase enzyme used in the treatment of Gaucher disease type 1. In addition to Elelyso, the company has developed a variety of pipeline products and patented protein expression technology that has the potential to enable faster and more efficient production of biological products. It also has research and development agreements with other biopharmaceutical companies and cooperative agreements with research institutions. Overall, Protalix Biotherapeutics Inc is well-positioned to continue growing and expanding its leading position in the industry.
odotettu liikevaihto Protalix Biotherapeutics on 82,14 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Protalix Biotherapeutics on 19,30 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Protalix Biotherapeutics:n hinta-voitto-suhde (P/E) on tällä hetkellä 12,01. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Protalix Biotherapeutics-osakkeen arvostusta.
Protalix Biotherapeutics:n hinta-myynti-suhde (P/S) on tällä hetkellä 2,82. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Protalix Biotherapeutics-osakkeen arvostuskennuslukuna.
Protalix Biotherapeutics:n Eulpool-laatuscore on 3/10.
Protalix Biotherapeutics:n ISIN on US74365A3095. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Protalix Biotherapeutics:n WKN on A2PWSL. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Protalix Biotherapeutics:n ticker on PLX. Tämä pörssinoteeraus käytetään Protalix Biotherapeutics-osakkeiden kauppaan pörssissä.
Protalix Biotherapeutics osake
Protalix Biotherapeutics vertaisryhmä
Protalix Biotherapeutics Ticker
Protalix Biotherapeutics FIGI
Kaikki tunnusluvut ja syvällinen analyysi Protalix Biotherapeutics:sta
Meidän osakeanalyysimme Protalix Biotherapeutics-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Protalix Biotherapeutics:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: